The current status of the use of biological medicine in the treatment of adult onset morbus still, Wegeners granulomatosis and systemic lupus erythematosus (SLE) is reviewed. The need for controlled trials is emphasized. Anti-CD20 treatment for SLE patients with kidney involvement and patients with Wegeners granulomatosis seems promising. Anti-TNF and IL1 receptor antagonist can control disease activity in most patients with adult morbus still.
|Translated title of the contribution||[Biological treatment of rare inflammatory rheumatic diseases]|
|Journal||Ugeskrift for Laeger|
|Number of pages||3|
|Publication status||Published - 9 Jun 2008|